GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition, such as the following: Type 2 diabetes High blood pressure High cholesterol Obstructive sleep apnea Cardiovascular disease that increases the risk of heart attack or stroke MASH, or metabolic dysfunctionassociated steatohepatitis, a form of liver inflammation Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, notes that qualifying for the medication based on heart disease aloneoften necessary for insurance coveragecan be challenging
Invited to give a presentation on GLUT2, he quickly gained the attention of people from Novo Nordisk when he briefly mentioned his work on the GLP-1 receptor at the end of his talk which he had not yet published
Because of that, patients tend to see dramatic results in a short period of time
Examples include people with PCOS, Crohns disease, certain forms of depression or anxiety tied to metabolic signaling, and patients with persistent inflammation where weight loss isnt the primary goal
This helps people feel full faster and for longer
By click-countinglistening to the audible clicks of the injector penpatients could self-administer smaller-than-prescribed amounts
